Related references
Note: Only part of the references are listed.CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells
Olga Latinovic et al.
VIROLOGY (2011)
CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity
Jasminka Sterjovski et al.
VIROLOGY (2011)
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies
Rachel A. McGovern et al.
AIDS (2010)
HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry
John C. Tilton et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Entry inhibitors in the treatment of HIV-1 infection
John C. Tilton et al.
ANTIVIRAL RESEARCH (2010)
A V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes the Human Immunodeficiency Virus Envelope Glycoprotein Trimer
Shi-Hua Xiang et al.
JOURNAL OF VIROLOGY (2010)
A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5
John C. Tilton et al.
JOURNAL OF VIROLOGY (2010)
HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
Jennifer M. Pfaff et al.
JOURNAL OF VIROLOGY (2010)
Enhanced CD4+cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection
Jessica Wade et al.
VIROLOGY (2010)
Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
Robert A. Ogert et al.
VIROLOGY (2010)
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes
Jasminka Sterjovski et al.
VIROLOGY (2010)
Coreceptors and HIV-1 Pathogenesis
Paul R. Gorry et al.
Current HIV/AIDS Reports (2010)
Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV
Nobuaki Shimizu et al.
AIDS (2009)
Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope
Kathryn M. Kitrinos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the Brain
Lachlan Gray et al.
JOURNAL OF VIROLOGY (2009)
Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist Vicriviroc
Robert A. Ogert et al.
JOURNAL OF VIROLOGY (2009)
Determinants Flanking the CD4 Binding Loop Modulate Macrophage Tropism of Human Immunodeficiency Virus Type 1 R5 Envelopes
Maria Jose Duenas-Decamp et al.
JOURNAL OF VIROLOGY (2009)
A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains
Samantha H. Johnston et al.
JOURNAL OF VIROLOGY (2009)
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
Cleo G. Anastassopoulou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12
Rebecca L. Dunfee et al.
RETROVIROLOGY (2009)
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities
Pavel Pugach et al.
VIROLOGY (2009)
Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
Reem Berro et al.
PLOS PATHOGENS (2009)
Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: Insights into the mechanism of allosteric inhibition
Kenji Maeda et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
Jasminka Sterjovski et al.
RETROVIROLOGY (2007)
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance
Soo-Huey Yap et al.
PLOS MEDICINE (2007)
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
Chih-chin Huang et al.
SCIENCE (2007)
Inference of macromolecular assemblies from crystalline state
Evgeny Krissinel et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Roy M. Gulick et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach et al.
VIROLOGY (2007)
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion
Elaine R. Thomas et al.
VIROLOGY (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
Jeannette M. Whitcomb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia
Rebecca L. Dunfee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Mechanisms of HIV-1 neurotropism
Rebecca Dunfee et al.
CURRENT HIV RESEARCH (2006)
Interaction of small molecule inhibitors of HIV-1 entry with CCR5
Christoph Seibert et al.
VIROLOGY (2006)
Structural and molecular interactions of CCR5 inhibitors with CCR5
K Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5Δ32 allele
L Gray et al.
JOURNAL OF VIROLOGY (2006)
Structure of a V3-containing HIV-1 gp120 core
CC Huang et al.
SCIENCE (2005)
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults
J Lalezari et al.
AIDS (2005)
Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome
L Gray et al.
VIROLOGY (2005)
Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages
PJ Peters et al.
JOURNAL OF VIROLOGY (2004)
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry
F Tsamis et al.
JOURNAL OF VIROLOGY (2003)
The emergence and characterization of macro phage-tropic SIV/HIV chimeric viruses (SHIVs) present in CD4(+) T cell-depleted rhesus monkeys
T Igarashi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor
EG Cormier et al.
JOURNAL OF VIROLOGY (2002)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate
PR Gorry et al.
JOURNAL OF VIROLOGY (2002)
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity
PR Gorry et al.
JOURNAL OF VIROLOGY (2001)
Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
XZ Yang et al.
JOURNAL OF VIROLOGY (2001)
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
T Dragic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo
B Etemad-Moghadam et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
